GlaxoSmithKline: Prepping for Battle Custom Case Solution & Analysis

Evidence Brief

Financial Metrics

• Total Sales 2001: 20.5 billion GBP, representing a 13 percent increase from the previous year.
• Research and Development Expenditure: 2.6 billion GBP.
• Paxil and Seroxat Sales: 2.4 billion GBP, contributing approximately 12 percent of total revenue.
• Augmentin Sales: 1.5 billion GBP.
• Operating Profit: 6.2 billion GBP.
• Estimated Revenue at Risk: Approximately 19 percent of total sales facing immediate generic competition.
• Market Share: 7 percent of the global pharmaceutical market.

Operational Facts

• Headcount: 100,000 employees total, with 16,000 dedicated to research and development.
• Sales Force: 40,000 representatives globally.
• Manufacturing: 108 sites operating across 41 countries.
• Organizational Structure: Transitioned to six Centers of Excellence for Drug Discovery (CEDDs).
• Product Pipeline: 44 new chemical entities and 33 vaccines in clinical development.
• Geographic Reach: Products sold in 140 countries.

Stakeholder Positions

• Jean-Pierre Garnier, Chief Executive Officer: Prioritizes EPS growth of 15 percent and demands a fundamental change in research productivity.
• Tachi Yamada, Chairman of Research and Development: Architect of the CEDD model, focused on creating small-team agility within a large organization.
• Generic Manufacturers: Actively challenging patents for Paxil and Augmentin in United States courts.
• Investors: Concerned about the revenue cliff following the expiration of core product patents.

Information Gaps

• The specific success rate of compounds within the new CEDD structure compared to the legacy model.
• Detailed breakdown of integration costs remaining from the Glaxo Wellcome and SmithKline Beecham merger.
• The exact marketing budget allocated to defend against generic entry for Augmentin.

Strategic Analysis

Core Strategic Question

• How can GlaxoSmithKline sustain double-digit earnings growth while its two primary revenue drivers face immediate generic erosion?
• Can a decentralized research model produce enough high-volume products to offset a 4 billion GBP revenue risk?

Structural Analysis

The pharmaceutical industry faces a structural shift where the cost of discovery exceeds the returns from traditional blockbusters. Applying the Five Forces framework reveals that the threat of substitutes is the primary driver of industry volatility. Generic manufacturers have optimized legal pathways to challenge patents, reducing the effective monopoly period for new drugs. GlaxoSmithKline possesses a massive sales force, but this asset becomes a fixed cost burden if the pipeline fails to deliver new products. The value chain is currently bottlenecked at the development stage, where the transition from discovery to clinical trials lacks speed.

Strategic Options

Preliminary Recommendation

The company must prioritize the CEDD optimization path while simultaneously increasing external licensing. The current pipeline cannot fill the 19 percent revenue gap through organic growth alone in the next 24 months. By utilizing the 40,000-person sales force as a platform for licensed products, the company can maintain cash flow while the CEDDs mature. This dual approach addresses the immediate patent cliff and the long-term productivity deficit.

Implementation Roadmap

Critical Path

The success of the new strategy depends on the rapid transition of the CEDDs from a structural concept to an operational engine. The following sequence is mandatory:

• Month 1: Finalize performance metrics for each CEDD, linking compensation directly to Phase II transition rates.
• Month 2: Establish a centralized licensing desk with the authority to bypass traditional committee reviews for assets under 100 million GBP.
• Month 3: Standardize clinical trial data protocols to ensure that information can be shared across the organization without administrative delay.
• Month 6: Review the manufacturing footprint to divest underutilized sites and reallocate capital to R&D.

Key Constraints

• Culture Clash: The legacy cultures of Glaxo Wellcome and SmithKline Beecham still exist. Scientists may resist the new autonomy if they fear it leads to a lack of job security.
• Regulatory Speed: No matter how fast the CEDDs work, the FDA and European regulators dictate the final timeline.
• Generic Litigation: A loss in the Augmentin patent case would accelerate the revenue decline by 12 months, requiring immediate budget cuts.

Risk-Adjusted Implementation Strategy

The plan assumes a 30 percent failure rate for products currently in Phase II. To mitigate this, the company will over-allocate resources to the three most promising CEDDs: Respiratory, Inflammation, and Infectious Diseases. This concentration of capital ensures that the most likely winners have the funding to reach the market ahead of schedule. A contingency fund of 500 million GBP will be held in reserve to acquire mid-stage biotech assets if internal Phase III trials fail.

Executive Review and BLUF

Bottom Line Up Front

GlaxoSmithKline faces a critical revenue shortfall as Paxil and Augmentin lose patent protection. The current decentralized research model is the correct long-term play, but it will not yield results fast enough to satisfy the 15 percent growth target. Leadership must pivot to a platform strategy. This involves using the massive global sales infrastructure to distribute licensed external products while the internal CEDD model stabilizes. Failure to secure at least two late-stage external assets within 12 months will result in an earnings miss and a subsequent valuation collapse. Efficiency in R&D is no longer an option; it is the only path to survival.

Dangerous Assumption

The most dangerous premise is that small-team biotech culture can be successfully replicated within a 100,000-person corporation. If the CEDDs become silos that do not share critical safety data, the company will face increased clinical failure rates and higher costs than the centralized model they replaced.

Unaddressed Risks

• Pricing Pressure: The analysis focuses on volume and patent life but ignores the increasing power of government payers to demand lower prices for even patented drugs.
• Sales Force Redundancy: If the pipeline does not deliver, the 40,000-person sales force becomes a liability. The cost of maintaining this headcount could consume the remaining margins.

Unconsidered Alternative

The team did not evaluate a full divestiture of the consumer healthcare business. Selling the consumer division would provide an immediate cash infusion of several billion pounds. This capital could be used to acquire a mid-sized pharmaceutical peer with an overlapping pipeline, providing immediate scale and a fresh set of patent-protected assets.

Verdict

APPROVED FOR LEADERSHIP REVIEW